Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Harm reduction services for people with SUD demonstrate efficacy, but they continue to encounter social stigma and barriers, according to a poster presentation at the RX and Illicit Drug Summit.
Harm reduction services for people with SUD demonstrate efficacy, but they continue to encounter social stigma and barriers, according to a poster presentation at the RX and Illicit Drug Summit.
Cape Cod Symposium faculty members Raghu Appasani, MD, PC, Gaetano Vaccaro, PhD, CSAT, and Kaci Hohmann, JD, explore the therapeutic benefits of psychedelics, how psychedelics function as adjunctive therapies, and key legal considerations.
Cape Cod Symposium faculty members Raghu Appasani, MD, PC, Gaetano Vaccaro, PhD, CSAT, and Kaci Hohmann, JD, explore the therapeutic benefits of psychedelics, how psychedelics function as adjunctive therapies, and key legal considerations.
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
